India, April 15 -- Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the European Commission has granted the amyloid-beta (A) monoclonal antibody Leqembi (lecanemab) Marketing Authorization in the European Union.
Lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E 4 (ApoE 4*) non-carriers or heterozygotes with confirmed amyloid pathology.1 The lecanemab MA applies to all 27 EU Member States as well as Iceland, Liechtenstein, and Norway.
Lecanemab is the only approved A monoclonal antibody that preferentially binds and clears toxic protofibrils** (soluble A aggregates), in addition to targeting ...